Literature DB >> 25843069

Association between visceral fat and inflammatory cytokines in reflux esophagitis.

Sang Wook Kim1.   

Abstract

Entities:  

Year:  2015        PMID: 25843069      PMCID: PMC4398251          DOI: 10.5056/jnm15029

Source DB:  PubMed          Journal:  J Neurogastroenterol Motil        ISSN: 2093-0879            Impact factor:   4.924


× No keyword cloud information.
The results of several previous studies have suggested that abdominal obesity is an important risk factor for reflux esophagitis.1,2 Among factors related to obesity, visceral fat is more associated with erosive esophagitis than body mass index (BMI).3 Physiologic abnormalities related to prolonged esophageal acid exposure have been found to occur more frequently in obese individuals than in those with normal weight. Obese subjects revealed abnormal esophageal manometric findings such as nonspecific motility disorder, nutcracker esophagus, and hypotensive lower esophageal sphincter as the most common manometric results.4 Transient relaxations of the lower esophageal sphincter (TRLES) is also reported to be more common in patients with obesity. The main stimulus for TRLES is gastric distension especially in the gastric fundus.5 Pandofino et al6 reported esophageal manometric findings suggesting that the pressure morphology within and across the esophagogastric junction were altered in obesity, which could augment the flow of gastric juices into the esophageal lumen. This anatomical disruption of the esophagogastric junction results in further hiatal hernia formation. Esophageal mucosal injury is associated with increased exposure to gastric acid. However, maintenance of chronic esophageal mucosal inflammation and esophageal metaplasia such as Barrett’s esophagus (BE) or esophageal carcinoma in obese subjects have been proposed to increase inflammatory cytokines from visceral adipose tissue.7 The relationship between obesity and esophageal neoplasia may be due to alterations in the secretion of adipokines such as adiponection and leptin. Adiponection has an anti-inflammatory effect and stimulates apoptosis, which shows inverse relationship between obesity and adiponection.8 Leptin, a satiety hormone, is secreted by adipocytes and gastric chief cells. Esophageal epithelial cells express leptin receptors. In an esophageal adenocarcinoma cell line, leptin has been shown to stimulate cell proliferation and inhibit apoptosis via cyclooxygenase-2 activation of the epidermal growth factor receptor.9 Several studies have suggested a positive association between plasma leptin and BE.10,11 Kendall et al12 reported that a high serum leptin level is associated with an increased risk of BE among men, but not women. No previous reports have documented the relationship between circulating cytokines and reflux esophagitis (RE). Recently, Nam13 conducted an interesting case-control study that suggested circulating cytokines were correlated with the risk of erosive esophagitis. They used abdominal visceral fat instead of BMI and plasma leptin level had a positive correlation with RE. The visceral fat/total fat ratio was used as an obesity index because there is no standard cut off value for defining obesity. The results indicated that both visceral fat and the visceral fat/total fat ratio were positively correlated with IL-6, IL-8, and IL-1β, but were negatively associated with adiponectin. Leptin showed no association with visceral fat, but had a strong association with the visceral fat/total fat ratio. Only visceral fat/100 and leptin were positively correlated with RE after adjusted analysis for both inflammatory cytokines and obesity indexes. Despite the positive correlation of visceral fat and leptin with risk of RE, they did not classified reflux symptom strength or severity of esophagitis. Moreover, cytokine has its effect through ligand mediate reaction. Elevated plasma levels of cytokines do not always reflect cytokine bioactivity in inflamed regions. Checking the receptor expression and cytokine levels in target tissue provides more information about cytokine-ligand mediated responses.14,15 In conclusion, obesity is an important risk factor for developing gastroesophageal reflux disease. Abdominal visceral fat is a more useful obesity index for RE than BMI. To clarify the role of circulating cytokines in obese subjects with RE, further studies with large populations are needed, which will also help elucidate the pathophysiology between obesity and RE.
  15 in total

1.  Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus.

Authors:  Joel H Rubenstein; Hal Morgenstern; Daniel McConell; James M Scheiman; Philip Schoenfeld; Henry Appelman; Laurence F McMahon; John Y Kao; Val Metko; Min Zhang; John M Inadomi
Journal:  Gastroenterology       Date:  2013-08-30       Impact factor: 22.682

2.  Association between GERD-related erosive esophagitis and obesity.

Authors:  Hang Lak Lee; Chang Soo Eun; Oh Young Lee; Yong Cheol Jeon; Ju Hyun Sohn; Dong Soo Han; Byung Chul Yoon; Ho Soon Choi; Joon Soo Hahm; Min Ho Lee; Dong Hoo Lee
Journal:  J Clin Gastroenterol       Date:  2008-07       Impact factor: 3.062

3.  Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities.

Authors:  Florian Rieder; Ling Cheng; Karen M Harnett; Amitabh Chak; Gregory S Cooper; Gerard Isenberg; Monica Ray; Jeffry A Katz; Andrew Catanzaro; Robert O'Shea; Anthony B Post; Richard Wong; Michael V Sivak; Thomas McCormick; Manijeh Phillips; Gail A West; Joseph E Willis; Piero Biancani; Claudio Fiocchi
Journal:  Gastroenterology       Date:  2006-10-12       Impact factor: 22.682

4.  Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury.

Authors:  Rhonda F Souza; Xiaofang Huo; Vivek Mittal; Christopher M Schuler; Susanne W Carmack; Hui Ying Zhang; Xi Zhang; Chunhua Yu; Kathy Hormi-Carver; Robert M Genta; Stuart J Spechler
Journal:  Gastroenterology       Date:  2009-08-04       Impact factor: 22.682

5.  Obesity: a challenge to esophagogastric junction integrity.

Authors:  John E Pandolfino; Hashem B El-Serag; Qing Zhang; Nimeesh Shah; Sudip K Ghosh; Peter J Kahrilas
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

Review 6.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

7.  Leptin and the risk of Barrett's oesophagus.

Authors:  B J Kendall; G A Macdonald; N K Hayward; J B Prins; I Brown; N Walker; N Pandeya; A C Green; P M Webb; D C Whiteman
Journal:  Gut       Date:  2008-01-04       Impact factor: 23.059

8.  Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation.

Authors:  Olorunseun Ogunwobi; Gabriel Mutungi; Ian L P Beales
Journal:  Endocrinology       Date:  2006-06-01       Impact factor: 4.736

Review 9.  Adiponectin and cancer: a systematic review.

Authors:  I Kelesidis; T Kelesidis; C S Mantzoros
Journal:  Br J Cancer       Date:  2006-05-08       Impact factor: 7.640

10.  The effect of abdominal visceral fat, circulating inflammatory cytokines, and leptin levels on reflux esophagitis.

Authors:  Su Youn Nam; Il Ju Choi; Kum Hei Ryu; Bum Joon Park; Young-Woo Kim; Hyun Beom Kim; Jeong Seon Kim
Journal:  J Neurogastroenterol Motil       Date:  2015-03-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.